Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukin-6 values in endotracheal and pleural fluids

Am J Hematol. 2022 Mar 1;97(3):E81-E83. doi: 10.1002/ajh.26433. Epub 2021 Dec 14.

Slimane Allali^{1

2

3}, Stéphanie Chhun⁴, Mariane de Montalembert^{1

3}, Claire Heilbronner⁵, Melissa Taylor^{1

3}, Joséphine Brice^{1

3}, Juliette Elie^{1

2}, Rachel Rignault-Bricard^{2

3}, Thiago Trovati Maciel^{2

3}, Judith Chareyre⁵, Olivier Hermine^{2

3

6}

¹ Department of General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker-Enfants Malades Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France.
² Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Université de Paris, Imagine Institute, Inserm U1163, Paris, France.
³ Laboratory of Excellence GR-Ex, Paris, France.
⁴ Laboratory of Immunology, Necker-Enfants Malades Hospital, AP-HP, Université de Paris, INEM Institute, Inserm U1151, Paris, France.
⁵ Department of Pediatric Intensive Care, Necker-Enfants Malades Hospital, AP-HP, Université de Paris, Paris, France.
⁶ Department of Hematology, Necker-Enfants Malades Hospital, AP-HP, Université de Paris, Paris, France.

No abstract available

Publication types